The nature of selective neuronal vulnerability represents a fundamental question in the pathophysiology of Alzheimer?s disease (AD). b-amyloid (Ab) is a hallmark pathology of AD, yet some cell types are very resistant to Ab toxicity, and about 30% of elderly individuals remain cognitively normal despite Ab accumulation. Differential gene expression among cell types, and among individuals likely contributes to selective vulnerability or resilience. Discoveries from our laboratories provide novel, compelling examples of disease dependent, cell type specific gene expression in AD. Using massively-parallel droplet based single nuclei transcriptomic sequencing (snRNAseq), we discovered that RBFOX1, a RNA binding protein involved in stress granule, and together with two previously known AD genes, ApoE and GFAP are selectively upregulated in astrocytes in AD brain. This proposal will use snRNAseq to elucidate cell type selective transcriptomes in entorhinal cortex from AD and control cases. This work will lead to fundamental advances in our knowledge of cell type specific genes regulating the pathophysiology of neurons and glial cells in AD.

Public Health Relevance

This proposal will identify genes that contribute to disease progression in Alzheimer?s disease; these approaches could lead to novel gene therapies to control and perhaps reverse the relentless brain degeneration that causes dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Project #
3R61DA047032-02S1
Application #
9880888
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Satterlee, John S
Project Start
2018-08-15
Project End
2021-05-31
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Boston University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
049435266
City
Boston
State
MA
Country
United States
Zip Code
02215